Cargando…
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood and adolescence. Refractory/relapsed RMS patients present a bad prognosis that combined with the lack of specific biomarkers impairs the development of new therapies. Here, we utilize dynamic BH3 profiling (DBP), a functional...
Autores principales: | Alcon, Clara, Manzano-Muñoz, Albert, Prada, Estela, Mora, Jaume, Soriano, Aroa, Guillén, Gabriela, Gallego, Soledad, Roma, Josep, Samitier, Josep, Villanueva, Alberto, Montero, Joan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429859/ https://www.ncbi.nlm.nih.gov/pubmed/32801295 http://dx.doi.org/10.1038/s41419-020-02887-y |
Ejemplares similares
-
MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment
por: Alcon, Clara, et al.
Publicado: (2022) -
Notch, Wnt, and Hedgehog Pathways in Rhabdomyosarcoma: From Single Pathways to an Integrated Network
por: Roma, Josep, et al.
Publicado: (2012) -
Targeting the Hedgehog Pathway in Rhabdomyosarcoma
por: Zarzosa, Patricia, et al.
Publicado: (2023) -
Hedgehog Pathway Inhibition Hampers Sphere and Holoclone Formation in Rhabdomyosarcoma
por: Almazán-Moga, Ana, et al.
Publicado: (2017) -
Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells
por: Erdogdu, Ufuk, et al.
Publicado: (2021)